Search clinical trials for: androgen

Total 1825 results

National Cancer Center Hospital East
Bayer Yakuhin, Ltd.

Active, not recruiting

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Salivary Gland Cancer

Japan
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)

Prostate Cancer

United States, France, Poland, Ukraine, United Kingdom, China, Spain, Argentina, Israel, Mexico, Romania, Turkey, Korea, Republic of, Japan, Sweden, Canada, Russian Federation, Brazil, Germany, Hungary, Czechia, Australia
Providence Health & Services
Bristol-Myers Squibb; Memorial Sloan Kettering Cancer Center

Active, not recruiting

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Breast Cancer | Breast Carcinoma | Breast Neoplasm Female | Breast Tumor

United States
Janssen Pharmaceutical K.K.

Active, not recruiting

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Prostatic Neoplasms

Japan
Aragon Pharmaceuticals, Inc.

Active, not recruiting

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Prostatic Neoplasms

United States, France, Poland, Taiwan, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Israel, Mexico, Malaysia, Romania, Turkey, Canada, Netherlands, Korea, Republic of, Brazil, Russian Federation, Argentina, Sweden, Czechia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Prostatic Neoplasms

China
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU)

Salivary Gland Neoplasms

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

Prostatic Neoplasms

United States, Italy, Czechia, Israel, Japan, Taiwan, Korea, Republic of, United Kingdom, France, Spain, Germany, Australia, Canada, Brazil, Russian Federation, Argentina, Netherlands, Poland
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Advanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)

United States, Belgium, Canada, Italy, Spain, United Kingdom
Bayer

Active, not recruiting

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC)

Metastatic Hormone-sensitive Prostate Cancer

United States
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

Korea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
Praful Ravi, MB BCHir, MRCP
Eli Lilly and Company; Bayer

Active, not recruiting

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Non-metastatic Prostate Cancer

United States
Bayer
Orion Corporation, Orion Pharma

Active, not recruiting

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE)

Prostatic Neoplasms

China, Russian Federation, Taiwan, Latvia, India, Australia, Brazil, Canada, Chile, Lithuania, New Zealand, Peru, South Africa, Spain, Ukraine
National Cancer Institute (NCI)

Completed

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Prostatic Neoplasms

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
University of California, San Francisco
Myovant Sciences GmbH

Completed

Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Patrick C. Walsh Fund

Active, not recruiting

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Active, not recruiting

Radiation and Androgen Ablation for Prostate Cancer

Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Active, not recruiting

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Castrate Sensitive Prostate Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
Emory University
National Cancer Institute (NCI)

Active, not recruiting

RElugolix VErsus LeUprolide Cardiac Trial (REVELUTION)

Biochemically Recurrent Prostate Carcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC... and other conditions

United States
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)

Prostatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic Neoplasms

United States, Canada
The Netherlands Cancer Institute

Terminated

Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer (DOP)

Prostatic Neoplasms

Netherlands
University of Wisconsin, Madison
Merck Sharp & Dohme LLC; Prostate Cancer Foundation; Madison Vaccines, Inc

Active, not recruiting

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
McGill University Health Centre/Research Institute...

Withdrawn

Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids (eTAPE)

Endometriosis | Fibroids

Canada
University Hospital, Gentofte, Copenhagen

Completed

Effect of PROGRESSive Training and Teststerone in Older Frail Men (PROGRESS)

Muscle Weakness

Denmark
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Stand Up To Cancer; High Impact Clinical Research Support...

Completed

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States
University of Chicago

Active, not recruiting

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Prostate Cancer

United States
Carelon Research

Terminated

Use of Oxandrolone to Promote Growth in Infants With HLHS

Congenital Heart Disease | Hypoplastic Left Heart

United States, Canada
Institut Universitari Dexeus

Terminated

Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial (T-TRANSPORT)

Infertility | Poor Ovarian Response

Spain, Switzerland, Belgium, Denmark
Suzhou Koshine Biomedica, Inc.

Completed

To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

Alopecia

China
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
University of Chicago
Janssen, LP

Suspended

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Recurrent Prostate Carcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage I Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States, Ireland
University of Kansas Medical Center
Oncology Nursing Society

Completed

Sleep Hygiene Education, ReadiWatchTM Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia Effect, on Symptom Relief for Men With Prostate Cancer Receiving Androgen Deprivation Therapy (SHERE-Relief 2)

Fatigue | Cognitive Impairment | Sleep Disturbance | Prostate Cancer

United States
Eurofarma Laboratorios S.A.

Active, not recruiting

Treatment of Androgenetic Alopecia in Men for 24 Weeks (MINOX)

Alopecia

Brazil
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Prostate Cancer

United States
Andrew McDonald
National Cancer Institute (NCI)

Active, not recruiting

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer (RAD 2003)

Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Prostate Cancer | Neoplasms of Prostate | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
Sunnybrook Health Sciences Centre

Active, not recruiting

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Prostate Cancer

Canada
Dana-Farber Cancer Institute
Janssen Pharmaceutica

Active, not recruiting

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Prostate Cancer

United States
Eunice Kennedy Shriver National Institute of Child...

Completed

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia (CAH)

United States
MacroGenics

Active, not recruiting

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors (Tamarack)

Melanoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Malignant Melanoma | Non-small Cell Carcinoma | Oral Squamous Cell Carcinoma | Small Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Castration-Resistant... and other conditions

Spain, Australia, United States, Korea, Republic of, France, United Kingdom, Italy, Belgium, Poland
University of California, Los Angeles
Oregon Health and Science University

Completed

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

Polycystic Ovary Syndrome (PCOS)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Metastatic Malignant Neoplasm in Lymph Node | Prostate Ductal Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology; Cancer and Leukemia Group B

Active, not recruiting

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Prostate Cancer

United States, Canada, China, Israel

Search clinical trials for: androgen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations